What is Januvia?
Januvia, also known as Sitagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor manufactured by Merck. Januvia was introduced to the market in October of 2006 as a once-daily prescription drug used to treat those diagnosed with Type-2 diabetes. If used in conjunction with proper diet and exercise it helps lower blood sugar levels in patients with type 2 diabetes. However, shortly after it was introduced to the market, Januvia was linked to pancreatic disease such as cancer.